个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Dong Renshun[1,2,3] * ; Wang Tianci[1,2,3] * ; Dong Wei[1,2,3,4] * ; Zhu He[1,2,3,4] ; Liu Qiumeng[1,2,3] ; Liang Huifang[1,2,3,4] ; Chen Xiaoping[1,2,3,4,*1] ; Zhang Bixiang[1,2,3,4,*1] ; Zhang Xuewu[1,2,3,4,*1] ;
单位： [1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China [2]Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China [3]Hubei Province for the Clinical Medicine Research Center of Hepatic Surgery, Wuhan, Hubei 430030, China [4]Key Laboratory of Organ Transplantation, Ministry of Education/NHC Key Laboratory of Organ Transplantation/Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei 430030, China
出处：
DOI： 10.1016/j.biopha.2024.116366
ISSN：

关键词： PTPRE inhibitor Hepatocellular carcinoma Sorafenib Organoid

摘要：
Hepatocellular carcinoma (HCC) has a poor prognosis, and the efficacy of current therapeutic strategies is extremely limited in advanced diseases. Our previous study reported that protein tyrosine phosphatase receptor epsilon (PTPRE) is a promoting factor in HCC progression. In this study, our objective was to evaluate the treatment effect of PTPRE inhibitors in different HCC preclinical models. Our results indicated that the PTPRE inhibitory compound 63 (Cpd-63) inhibited tumor cell proliferation, migration, and HCC organoid growth. Mechanism research revealed that Cpd-63 could inhibit the expression of MYC and MYC targets by inhibiting the activation of SRC. Additionally, we found that Cpd-63 could improve the response of sorafenib in HCC cells. In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management.Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

基金：
This work was supported by grants from the National Natural Science Foundation of China (82003093), Hubei Provincial Natural Science Foundation of China (2023AFB774), and the Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province (CXPJJH12000001-2020326).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 1 区 药学 2 区 医学：研究与实验
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：研究与实验 2 区 药学
JCR分区：
出版当年[2022]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者单位： [1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China [2]Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China [3]Hubei Province for the Clinical Medicine Research Center of Hepatic Surgery, Wuhan, Hubei 430030, China
共同第一作者：
通讯作者：
通讯机构： [1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China [2]Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China [3]Hubei Province for the Clinical Medicine Research Center of Hepatic Surgery, Wuhan, Hubei 430030, China [4]Key Laboratory of Organ Transplantation, Ministry of Education/NHC Key Laboratory of Organ Transplantation/Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei 430030, China [*1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
推荐引用方式(GB/T 7714)：
Dong Renshun,Wang Tianci,Dong Wei,et al.Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma[J].BIOMEDICINE & PHARMACOTHERAPY.2024,173:116366.doi:10.1016/j.biopha.2024.116366.
APA：
Dong Renshun,Wang Tianci,Dong Wei,Zhu He,Liu Qiumeng...&Zhang Xuewu.(2024).Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.BIOMEDICINE & PHARMACOTHERAPY,173,
MLA：
Dong Renshun,et al."Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma".BIOMEDICINE & PHARMACOTHERAPY 173.(2024):116366

相关文献

[1]Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma [2]Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. [3]Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved? [4]Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study [5]Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial [6]The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects [7]DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma [8]Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma [9]索拉非尼治疗晚期原发性肝癌的临床观察 [10]Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient

资源点击量：426 今日访问量：2 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）